Letter
Mycophenolate mofetil and hydroxychloroquine: An effective treatment for recalcitrant cutaneous lupus erythematosus

https://doi.org/10.1016/j.jaad.2011.08.036Get rights and content

References (3)

There are more references available in the full text version of this article.

Cited by (9)

  • Cutaneous lupus erythematosus: A review of the literature

    2019, International Journal of Women's Dermatology
    Citation Excerpt :

    A retrospective analysis of 24 patients with treatment-resistant CLE showed some clinical response in all patients and resolution or near resolution of disease activity in 62% of patients (Gammon et al., 2011). MMF in combination with hydroxychloroquine has been trialed successfully in a small case series of three cases (Sadlier et al., 2012). Case reports have shown successful treatment of DLE lesions with azathioprine (Okon and Werth, 2013); however, there are no controlled trials to support routine use in CLE.

  • Which dose of steroids and which cytotoxics for severe lupus?

    2014, Presse Medicale
    Citation Excerpt :

    Cutaneous improvement is usually noticeable within 2 months of treatment. The evidence supporting the management of severe cutaneous and discoid lupus erythematosus with mycophenolate mofetil is based on open label placebo-controlled trials, case series and case reports, which recommend an average dose of MMF 1–3 g per day [36–39]. Clinical response may take approximately 3 months to become evident.

  • Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus

    2013, Autoimmunity Reviews
    Citation Excerpt :

    Other immunosuppressive drugs not yet approved for the treatment of CLE are MMF and EC-MPS. So far, there are only a few case reports and retrospective studies showing that MMF is effective in treating different subtypes of CLE and skin manifestations in SLE [7,52,53]. In general, MMF is well tolerated.

  • Cutaneous Lupus Erythematosus: Progress and Challenges

    2020, Current Allergy and Asthma Reports
View all citing articles on Scopus

Funding sources: None.

Conflicts of interest: None declared.

View full text